A 12‐Week, Open Label, Multi‐Center Study to Evaluate the Clinical Efficacy and Safety of Silodosin on Voiding Dysfunction in Patients with Neurogenic Bladder
Authors:
- 19 November 2013
- journal article
- clinical trial
- Published by Wiley in LUTS: Lower Urinary Tract Symptoms
- Vol. 7 (1) , 27-31
Abstract
The purpose of this study is to evaluate clinical effect and safety of α1A -adrenoceptor blocker, silodosin, in patients with voiding dysfunction caused by neurogenic bladder. From April 2011 to January 2012, patients who were diagnosed as potential voiding dysfunction associated with neurogenic bladder, aged ≥ 20 years were enrolled. Silodosin (8 mg/day) was administered once daily in the morning with food. The efficacy was assessed at the baseline and after 12 weeks of the treatment having following parameters of international prostate symptom score and other measures including the maximum flow rate and the postvoid residual urine volume. A total of 97 patients were screened and 95 were enrolled. Of these 95 patients, 82 patients were completed and included in analysis. After 12-weeks of treatment, mean total international prostate symptom score decreased significantly from 22.23 ± 6.80 to 14.98 ± 9.48 (P = 0.0002). Voiding symptoms and storage symptoms were also improved by decreasing in international prostate symptom score-QoL from 4.62 ± 0.92 to 3.48 ± 1.63 (P < 0.0001). Maximum flow rate increased significantly from 10.72 ± 2.66 to 15.14 ± 6.63 (P < 0.0001). The main adverse event was ejaculation disorder. No serious adverse events related to silodosin were noted. This study indicates that silodosin was significantly effective, well tolerated and safe in patients who have voiding dysfunction associated with neurogenic bladder.Keywords
Funding Information
- Korea Food and Drug Administration, Seoul, Korea (2330)
This publication has 19 references indexed in Scilit:
- Predictive factors for the effect of the α1‐D/A adrenoceptor antagonist naftopidil on subjective and objective criteria in patients with neurogenic lower urinary tract dysfunctionBJU International, 2010
- Efficacy and Safety of Tamsulosin for the Treatment of Non-neurogenic Voiding Dysfunction in Females: A 8-Week Prospective StudyJournal of Korean Medical Science, 2010
- The Effect of Terazosin on Functional Bladder Outlet Obstruction in Women: A Pilot StudyJournal of Urology, 2006
- The Characteristics of Voiding Difficulty in Women and the Effect of TamsulosinKorean Journal of Urology, 2006
- Use of α1-Blockers in Female Functional Bladder Neck ObstructionUrologia Internationalis, 2005
- Tamsulosin: Efficacy and Safety in Patients With Neurogenic Lower Urinary Tract Dysfunction Due to Suprasacral Spinal Cord InjuryJournal of Urology, 2003
- Non-neurogenic female voiding dysfunctionCurrent Opinion in Urology, 2002
- Mode of action of α 1 ‐adrenoreceptor antagonists in the treatment of lower urinary tract symptomsBJU International, 2000
- EVIDENCE FOR PREDOMINANT MEDIATION OF α 1 -ADRENOCEPTOR IN THE TONUS OF ENTIRE URETHRA OF WOMENJournal of Urology, 1999
- A Multicenter Placebo-Controlled, Double-Blind Trial of Urapidil, an α-Blocker, on Neurogenic Bladder DysfunctionEuropean Urology, 1999